RxDoctor Payments Data

Kay Chandler, MD

Obstetrics & Gynecology · Little Rock, ARNPI 1922075746

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,142 of the $4,649 with a category attached, or 67.6%. 30 manufacturers reported payments, led by Minerva Surgical, Inc at 34.4% of the total. Reporting peaked in 2019 at $1,847 and has fallen 86.5% since, to $249 in 2025.

$4,649in general payments, 2019–2025

Across 174 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Minerva Surgical, Inc$2K
  • AbbVie$653
  • Astellas Pharma US Inc$418
  • Bayer$311
  • Aspira Women's Health Inc$181
  • Exeltis, USA Inc.$164
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$1,50032%
  • Food & beverage$3,14268%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,649 in reported general payments places this provider in the 80th percentile of 272 obstetrics & gynecology providers in Arkansas.

See all obstetrics & gynecology providers in Arkansas

Medicare billing

Part B allowed, 2024
$110,000
Medicare patients
444
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized342$11,404
Estradiol289$5,291
Liothyronine Sodium156$4,502
SynthroidLevothyroxine Sodium43$2,282
Np ThyroidThyroid,pork33$1,468
Estradiol (Once Weekly)Estradiol19$1,354
DottiEstradiol17$983
Estradiol (Twice Weekly)Estradiol14$975
Clobetasol Propionate20$951
ValacyclovirValacyclovir Hcl34$914
Levothyroxine Sodium90$422
Spironolactone49$368
Trazodone Hcl26$186
Nystatin11$127
Dicyclomine Hcl11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$653$2,28243 claims
Acella Pharmaceuticals, LLCNp Thyroid$15$1,46833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 272 obstetrics & gynecology providers in Arkansas.

Other obstetrics & gynecology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →